CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma
Clinical trial NCT07461831 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07461831
- Sponsor
- Beijing Tongren Hospital
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-01
- Primary completion
- 2026-04-18
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.